A new study on Breast Cancer is now available. According to news originating from Barcelona, Spain, by NewsRx correspondents, research stated, “Aromatase inhibitor (AI)-related bone loss is associated with increased fracture rates. Vitamin D might play a role in minimising this effect.”
Our news journalists obtained a quote from the research from IMIM, “We hypothesised that 25-hydroxy-vitamin D concentrations [25(OH)D] after 3 months supplementation might relate to bone loss after 1 year on AI therapy. We conducted a prospective cohort study from January 2006 to December 2011 of a consecutive sample of women initiating AI for early breast cancer who were ineligible for bisphosphonate therapy and stayed on treatment for 1 year (N#2). Serum 25(OH)D was measured at baseline and 3 months, and lumbar spine (LS) bone mineral density at baseline and 1 year. Subjects were supplemented with daily calcium (1 g) and vitamin D(3) (800 IU) and additional oral 16,000 IU every 2 weeks if baseline 25(OH)D was <30 ng/ml. Linear regression models were fitted to adjust for potential confounders. After 1 year on AI therapy, 232 participants experienced a significant 1.68 % [95 % CI 1.15-2.20 %] bone loss at LS (0.017 g/cm(2) [0.012-0.024], p<0.0001). Higher 25(OH)D at 3 months protected against LS bone loss (-0.5 % per 10 ng/ml [95 % CI -0.7 to -0.3 %], adjusted p=0.0001), and those who reached levels@ ng/ml had reduced bone loss by 1.70 % [95 % CI 0.4-3.0 %; adjusted p=0.005] compared to those with low 25(OH)D levels (<30 ng/ml). We conclude that improved vitamin D status using supplementation is associated with attenuation of AI-associated bone loss.”
According to the news editors, the researchers concluded: “For this population, the current Institute of Medicine target recommendation of 20 ng/ml might be too low to ensure good bone health.”
For more information on this research see: Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study. Breast Cancer Research and Treatment, 2012;133(3):1159-67. Breast Cancer Research and Treatment can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer – www.springer.com; Breast Cancer Research and Treatment – www.springerlink.com/content/0167-6806/)
The news correspondents report that additional information may be obtained from D. Prieto-Alhambra, URFOA-IMIM, Parc de Salut Mar, Parc de Recerca Biomedica de Barcelona, C, Dr Aiguader, 88, 2nd Floor, 08003 Barcelona, Spain (see also Breast Cancer).
The publisher’s contact information for the journal Breast Cancer Research and Treatment is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Spain, Europe, Barcelona, Cytochromes, Hemeproteins, Bone Research, Breast Cancer, Oxidoreductases, Enzyme Inhibitors, Aromatase Inhibitors, Steroid Hydroxylases, Enzymes and Coenzymes, Mixed Function Oxygenases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
2007 NewsRx.com. All Rights Reserved.Copyright 2012, Women’s Health Weekly via NewsRx.com